Literature DB >> 31266627

HBV/HDV Coinfection: A Challenge for Therapeutics.

Christopher Koh1, Ben L Da2, Jeffrey S Glenn3.   

Abstract

Chronic hepatitis D (CHD) results from an infection with the hepatitis B virus and hepatitis D virus (HDV). CHD is the most severe form of human viral hepatitis. Current treatment options consist of interferon alfa, which is effective only in a minority of patients. Study of HDV molecular virology has resulted in new approaches entering clinical trials, with phase-3 studies the most advanced. These include the entry inhibitor bulevirtide, the nucleic acid polymer REP 2139-Ca, the farnesyltransferase inhibitor lonafarnib, and pegylated interferon lambda. This article summarizes the available data on these emerging therapeutics. Published by Elsevier Inc.

Entities:  

Keywords:  Cirrhosis; Clinical trials; Hepatitis B; Hepatitis D; Therapeutics

Mesh：

Substances：

Year:  2019        PMID： 31266627      PMCID： PMC6659751          DOI： 10.1016/j.cld.2019.04.005

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  89 in total

1.  Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.

Authors:  J E Mata; M R Bishop; S R Tarantolo; C R Angel; S A Swanson; P L Iversen
Journal:  J Toxicol Clin Toxicol       Date:  2000

2.  Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.

Authors:  Cihan Yurdaydin; Onur Keskin; Çagdas Kalkan; Fatih Karakaya; Aysun Çaliskan; Gökhan Kabaçam; F Oguz Önder; Senem Karatayli; Ersin Karatayli; Xheni Deda; Hakan Bozkaya; A Mithat Bozdayi; Ramazan Idilman
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

3.  Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition.

Authors:  Azeneth Barrera; Bernadette Guerra; Lena Notvall; Robert E Lanford
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep).

Authors:  H L Janssen; J T Brouwer; F Nevens; J M Sanchez-Tapias; A Craxi; S Hadziyannis
Journal:  BMJ       Date:  1993-01-09

5.  Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes.

Authors:  Tatyana Kushner; Marina Serper; David E Kaplan
Journal:  J Hepatol       Date:  2015-05-08       Impact factor: 25.083

Review 6.  Structure and replication of hepatitis delta virus RNA.

Authors:  J M Taylor
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

7.  The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics.

Authors:  A Blank; A Eidam; M Haag; N Hohmann; J Burhenne; M Schwab; Sfj van de Graaf; M R Meyer; H H Maurer; K Meier; J Weiss; T Bruckner; A Alexandrov; S Urban; G Mikus; W E Haefeli
Journal:  Clin Pharmacol Ther       Date:  2017-06-21       Impact factor: 6.875

8.  Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen.

Authors:  S M Cole; E J Gowans; T B Macnaughton; P D Hall; C J Burrell
Journal:  Hepatology       Date:  1991-05       Impact factor: 17.425

9.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

10.  Transgenic mice support replication of hepatitis delta virus RNA in multiple tissues, particularly in skeletal muscle.

Authors:  J M Polo; K S Jeng; B Lim; S Govindarajan; F Hofman; F Sangiorgi; M M Lai
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103
View more
  10 in total

Review 1.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Authors:  Mindie H Nguyen; Grace Wong; Edward Gane; Jia-Horng Kao; Geoffrey Dusheiko
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

Review 2.  Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al Mahtab; Sakirul Khan; Osamu Yoshida; Julio Cesar Aguilar; Guillen Nieto Gerardo; Yoichi Hiasa
Journal:  Vaccines (Basel)       Date:  2022-05-10

Review 3.  Epitranscriptomic marks: Emerging modulators of RNA virus gene expression.

Authors:  Rachel Netzband; Cara T Pager
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-11-06       Impact factor: 9.957

4.  Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.

Authors:  Thomas R O'Brien; David L Thomas; Sarah S Jackson; Ludmila Prokunina-Olsson; Raymond P Donnelly; Rune Hartmann
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

5.  Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada.

Authors:  Carla Osiowy; Ken Swidinsky; Sarah Haylock-Jacobs; Matthew D Sadler; Scott Fung; David Wong; Gerald Y Minuk; Karen E Doucette; Philip Wong; Edward Tam; Curtis Cooper; Alnoor Ramji; Mang Ma; Carmine Nudo; Keith Tsoi; Carla S Coffin
Journal:  JHEP Rep       Date:  2022-02-22

Review 6.  Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.

Authors:  Laura A Novotny; John Grayson Evans; Lishan Su; Haitao Guo; Eric G Meissner
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

Review 7.  Human hepatitis D virus-specific T cell epitopes.

Authors:  Matin Kohsar; Johanna Landahl; Christoph Neumann-Haefelin; Julian Schulze Zur Wiesch
Journal:  JHEP Rep       Date:  2021-04-23

Review 8.  Present and future management of viral hepatitis.

Authors:  Rocío González Grande; Inmaculada Santaella Leiva; Susana López Ortega; Miguel Jiménez Pérez
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

9.  Binding of Hepatitis B Virus Pre-S1 Domain-Derived Synthetic Myristoylated Peptide to Scavenger Receptor Class B Type 1 with Differential Properties from Sodium Taurocholate Cotransporting Polypeptide.

Authors:  Shuji Hinuma; Shun'ichi Kuroda
Journal:  Viruses       Date:  2022-01-07       Impact factor: 5.048

Review 10.  Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic.

Authors:  Caterina Sagnelli; Mariantonietta Pisaturo; Caterina Curatolo; Alessio Vinicio Codella; Nicola Coppola; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.